Alan List, new Precision BioSciences CMO, in 2019 (Diane Bondareff/AP Images for Moffitt Cancer Center)

Eli Lil­ly-part­nered biotech taps star in­ves­ti­ga­tor Alan List as CMO — a year af­ter he re­signed from Mof­fitt over Chi­na scan­dal

Af­ter lay­ing low for more than a year fol­low­ing a scan­dal that led to his ouster, for­mer Mof­fitt Can­cer Cen­ter CEO Alan List has emerged in the front­lines of biotech.

An ex­pert in hema­tol­ogy and on­col­o­gy drug de­vel­op­ment known as a lead in­ves­ti­ga­tor for Cel­gene’s block­buster Revlim­id, List is swap­ping “clin­i­cal tri­als con­sul­tant” for the chief med­ical of­fi­cer ti­tle at Pre­ci­sion Bio­Sciences — a Eli Lil­ly-part­nered biotech boast­ing a new gene edit­ing ap­proach to cell and gene cor­rec­tion ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.